title: Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.
abstract: Interferon-alpha (IFN-α) is an immunomodulatory cytokine that is used clinically for the treatment of melanoma in the adjuvant setting. The cellular actions of IFN-α are regulated by the suppressors of cytokine signaling (SOCS) family of proteins. We hypothesized that the anti-tumor activity of exogenous IFN-α would be enhanced in SOCS1-deficient mice. SOCS1-deficient (SOCS1(-/-)) or control (SOCS1(+/+)) mice on an IFN-γ(-/-) C57BL/6 background bearing intraperitoneal (i.p.) JB/MS murine melanoma cells were treated for 30 days with i.p. injections of IFN-A/D or PBS (vehicle). Log-rank Kaplan-Meier survival curves were used to evaluate survival. Tumor-bearing control SOCS1(+/+) mice receiving IFN-A/D had significantly enhanced survival versus PBS-treated mice (P = 0.0048). The anti-tumor effects of IFN-A/D therapy were significantly enhanced in tumor-bearing SOCS1(-/-) mice; 75% of these mice survived tumor challenge, whereas PBS-treated SOCS1(-/-) mice all died at 13-16 days (P = 0.00038). Antibody (Ab) depletion of CD8(+) T cells abrogated the anti-tumor effects of IFN-A/D in SOCS1(-/-) mice as compared with mice receiving a control antibody (P = 0.0021). CD4(+) T-cell depletion from SOCS1(-/-) mice also inhibited the effects of IFN-A/D (P = 0.0003). IFN-A/D did not alter expression of CD80 or CD86 on splenocytes of SOCS1(+/+) or SOCS1(-/-) mice, or the proportion of T regulatory cells or myeloid-derived suppressor cells in SOCS1(+/+) or SOCS1(-/-) mice. An analysis of T-cell function did reveal increased proliferation of SOCS1-deficient splenocytes at baseline and in response to mitogenic stimuli. These data suggest that modulation of SOCS1 function in T-cell subsets could enhance the anti-tumor effects of IFN-α in the setting of melanoma.
authors: Department of Surgery, Columbus, OH 3210, Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH 43210, USA.
authors: Kristan D
authors: KD
authors: Guenterberg
authors: Gregory B
authors: GB
authors: Lesinski
authors: Bethany L
authors: BL
authors: Mundy-Bosse
authors: Volodymyr I
authors: VI
authors: Karpa
authors: Alena Cristina
authors: AC
authors: Jaime-Ramirez
authors: Lai
authors: L
authors: Wei
authors: William E
authors: WE
authors: Carson
references: N Engl J Med. 2006 Feb 16;354(7):709-18
references: 16481638
references: Cancer Sci. 2009 Apr;100(4):730-6
references: 19469017
references: J Pathol. 2003 Jul;200(3):383-95
references: 12845635
references: Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14395-9
references: 9826711
references: J Clin Invest. 2003 Jul;112(2):170-80
references: 12865406
references: J Clin Oncol. 2004 Jan 1;22(1):11-4
references: 14665613
references: N Engl J Med. 1998 Feb 26;338(9):616-8
references: 9475772
references: Cell Signal. 2007 Apr;19(4):806-16
references: 17126530
references: Nat Rev Immunol. 2002 Jun;2(6):410-6
references: 12093007
references: Immunity. 2003 Apr;18(4):475-87
references: 12705851
references: Nat Immunol. 2005 Jul;6(7):715-21
references: 15924143
references: Blood. 2008 Apr 15;111(8):4233-44
references: 18272812
references: J Immunol. 2002 Jan 15;168(2):689-95
references: 11777962
references: Br J Dermatol. 2004 Feb;150(2):179-85
references: 14996086
references: J Clin Invest. 2006 Jan;116(1):90-100
references: 16357940
references: Semin Oncol. 1998 Feb;25(1 Suppl 1):14-22
references: 9482536
references: J Immunol. 2007 Apr 15;178(8):4832-45
references: 17404264
references: J Natl Cancer Inst. 2004 Sep 1;96(17):1331-42
references: 15339971
references: Science. 1994 Jun 3;264(5164):1415-21
references: 8197455
references: EMBO J. 1999 Jan 15;18(2):375-85
references: 9889194
references: Cancer Res. 1982 Aug;42(8):3157-63
references: 7093959
references: J Interferon Cytokine Res. 1998 Aug;18(8):549-54
references: 9726434
references: EMBO J. 1999 Mar 1;18(5):1309-20
references: 10064597
references: Cancer Immunol Immunother. 2005 Sep;54(9):815-25
references: 15668815
references: Cell. 1999 Sep 3;98(5):609-16
references: 10490100
references: J Immunol. 2008 Mar 15;180(6):3746-56
references: 18322180
references: J Exp Med. 2006 Jun 12;203(6):1391-7
references: 16717119
references: Hematol Oncol Clin North Am. 1998 Aug;12(4):877-902, viii
references: 9759585